MedTrace Logo

1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients

NCT02334722 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2021-12-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if there are any differences in patient reported neurotoxicity between patients who receive Levetiracetam tablets for one week after surgery to remove a brain tumor versus those who receive Levetiracetam tablets for six weeks after surgery. Specifically, we will see if one group has less side effects than the other, and whether or not one group has more seizures than the other.

Conditions

Interventions

DRUG

Levetiracetam

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Maryam Rahman, MS, MD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-05
Primary Completion
2020-10-07
Completion
2020-10-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02334722 on ClinicalTrials.gov